Alan Schatzberg - Publications

Affiliations: 
Psychiatry Stanford University, Palo Alto, CA 

221 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Watson KT, Keller J, Spiro CM, Satz IB, Goncalves SV, Pankow H, Kosti I, Lehallier B, Sequeira A, Bunney WE, Rasgon NL, Schatzberg AF. Proteomic profiles of cytokines and chemokines in moderate to severe depression: Implications for comorbidities and biomarker discovery. Brain, Behavior, & Immunity - Health. 36: 100731. PMID 38435722 DOI: 10.1016/j.bbih.2024.100731  0.364
2023 Lii TR, Smith AE, Flohr JR, Okada RL, Nyongesa CA, Cianfichi LJ, Hack LM, Schatzberg AF, Heifets BD. Randomized trial of ketamine masked by surgical anesthesia in patients with depression. Nature Mental Health. 1: 876-886. PMID 38188539 DOI: 10.1038/s44220-023-00140-x  0.378
2023 Vreijling SR, Chin Fatt CR, Williams LM, Schatzberg AF, Usherwood T, Nemeroff CB, Rush AJ, Uher R, Aitchison KJ, Köhler-Forsberg O, Rietschel M, Trivedi MH, Jha MK, Penninx BWJH, Beekman ATF, et al. Features of immunometabolic depression as predictors of antidepressant treatment outcomes: pooled analysis of four clinical trials. The British Journal of Psychiatry : the Journal of Mental Science. 1-9. PMID 38130122 DOI: 10.1192/bjp.2023.148  0.401
2023 McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, Gorwood P, Ho R, Kasper S, Kennedy SH, Ly-Uson J, Mansur RB, McAllister-Williams RH, Murrough JW, Nemeroff CB, ... ... Schatzberg AF, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 22: 394-412. PMID 37713549 DOI: 10.1002/wps.21120  0.586
2023 Schatzberg AF, Mathew SJ. The why, when, where, how, and so what of so-called rapidly acting antidepressants. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 37460770 DOI: 10.1038/s41386-023-01647-8  0.349
2023 Hack LM, Tozzi L, Zenteno S, Olmsted AM, Hilton R, Jubeir J, Korgaonkar MS, Schatzberg AF, Yesavage JA, O'Hara R, Williams LM. A Cognitive Biotype of Depression and Symptoms, Behavior Measures, Neural Circuits, and Differential Treatment Outcomes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. Jama Network Open. 6: e2318411. PMID 37318808 DOI: 10.1001/jamanetworkopen.2023.18411  0.356
2023 Reich J, Schatzberg A. Childhood maladaptive coping mechanisms and the subsequent development of depression. Clinical Psychology & Psychotherapy. PMID 36652398 DOI: 10.1002/cpp.2831  0.411
2022 Schatzberg AF. An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression. The American Journal of Psychiatry. 179: 890-891. PMID 36453033 DOI: 10.1176/appi.ajp.20220812  0.394
2021 Sforzini L, Worrell C, Kose M, Anderson IM, Aouizerate B, Arolt V, Bauer M, Baune BT, Blier P, Cleare AJ, Cowen PJ, Dinan TG, Fagiolini A, Ferrier IN, Hegerl U, ... ... Schatzberg AF, et al. A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Molecular Psychiatry. PMID 34907394 DOI: 10.1038/s41380-021-01381-x  0.339
2021 Cole EJ, Phillips AL, Bentzley BS, Stimpson KH, Nejad R, Barmak F, Veerapal C, Khan N, Cherian K, Felber E, Brown R, Choi E, King S, Pankow H, Bishop JH, ... ... Schatzberg AF, et al. Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. The American Journal of Psychiatry. appiajp202120101429. PMID 34711062 DOI: 10.1176/appi.ajp.2021.20101429  0.777
2021 Heifets BD, Bentzley BS, Williams N, Schatzberg AF. Unraveling the opioid actions of S-ketamine and R-ketamine: comment on Bonaventura et al. Molecular Psychiatry. PMID 34006965 DOI: 10.1038/s41380-021-01167-1  0.431
2020 Fischer AS, Holt-Gosselin B, Fleming SL, Hack LM, Ball TM, Schatzberg AF, Williams LM. Intrinsic reward circuit connectivity profiles underlying symptom and quality of life outcomes following antidepressant medication: a report from the iSPOT-D trial. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 33230268 DOI: 10.1038/s41386-020-00905-3  0.687
2020 Fischer AS, Tapert SF, Lee Louie D, Schatzberg AF, Singh MK. Cannabis and the Developing Adolescent Brain. Current Treatment Options in Psychiatry. 7: 144-161. PMID 32714742 DOI: 10.1007/S40501-020-00202-2  0.636
2020 Cole EJ, Stimpson KH, Bentzley BS, Gulser M, Cherian K, Tischler C, Nejad R, Pankow H, Choi E, Aaron H, Espil FM, Pannu J, Xiao X, Duvio D, Solvason HB, ... ... Schatzberg AF, et al. Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. The American Journal of Psychiatry. appiajp201919070720. PMID 32252538 DOI: 10.1176/Appi.Ajp.2019.19070720  0.768
2020 Sudheimer K, Duvio D, Shols E, Heinemeyer E, Williams N, O'Hara R, Schatzberg A. The Effects of Cortisol on Subgenual Cingulate Activity in Depression Biological Psychiatry. 87: S449. DOI: 10.1016/J.Biopsych.2020.02.1143  0.794
2020 Holt-Gosselin B, Fischer A, Fleming S, Hack L, Ball T, Schatzberg A, Williams LM. Functional Connectivity of Reward Circuitry is a Core Mechanistic Biomarker of Treatment Response and Quality of Life in Depression Biological Psychiatry. 87: S396-S397. DOI: 10.1016/J.Biopsych.2020.02.1014  0.726
2020 Fischer AS, Tapert SF, Louie DL, Schatzberg AF, Singh MK. Cannabis and the Developing Adolescent Brain Current Treatment Options in Psychiatry. 7: 144-161. DOI: 10.1007/s40501-020-00202-2  0.61
2019 Williams NR, Heifets BD, Bentzley BS, Blasey C, Sudheimer KD, Hawkins J, Lyons DM, Schatzberg AF. Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. Molecular Psychiatry. PMID 31467392 DOI: 10.1038/S41380-019-0503-4  0.749
2019 Heifets BD, Williams NR, Bentzley BS, Schatzberg AF. Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine's Antidepressant Effect. Jama Psychiatry. PMID 31042274 DOI: 10.1001/Jamapsychiatry.2019.0766  0.494
2019 Schatzberg AF. Scientific Issues Relevant to Improving the Diagnosis, Risk Assessment, and Treatment of Major Depression. The American Journal of Psychiatry. 176: 342-347. PMID 31039643 DOI: 10.1176/appi.ajp.2019.19030273  0.333
2019 Heifets BD, Williams NR, Blasey C, Sudheimer K, Rodriguez CI, Schatzberg AF. Rigorous Translational Models Are Key to Studying Ketamine's Antidepressant Mechanism: Response to Wang and Kaplin. The American Journal of Psychiatry. 176: 412. PMID 31039633 DOI: 10.1176/Appi.Ajp.2019.19010044R  0.713
2019 Heifets BD, Williams NR, Blasey C, Sudheimer K, Rodriguez CI, Schatzberg AF. Interpreting Ketamine's Opioid Receptor Dependent Effect: Response to Sanacora. The American Journal of Psychiatry. 176: 249-250. PMID 30818991 DOI: 10.1176/Appi.Ajp.2018.18091061R  0.707
2019 Heifets BD, Williams NR, Blasey C, Sudheimer K, Rodriguez CI, Schatzberg AF. Target Population, Dose, and Timing Considerations for Understanding Naltrexone's Subjective Effect: Response to Amiaz. The American Journal of Psychiatry. 176: 251-252. PMID 30818989 DOI: 10.1176/Appi.Ajp.2018.18111231R  0.693
2019 Meyer BM, Rabl U, Huemer J, Bartova L, Kalcher K, Provenzano J, Brandner C, Sezen P, Kasper S, Schatzberg AF, Moser E, Chen G, Pezawas L. Prefrontal networks dynamically related to recovery from major depressive disorder: a longitudinal pharmacological fMRI study. Translational Psychiatry. 9: 64. PMID 30718459 DOI: 10.1038/s41398-019-0395-8  0.677
2019 Sudheimer K, Duvio D, James D, Heinemeyer E, Pirog S, Williams N, Schatzberg A. F140. The Effects of Cortisol Administration on Emotion, Stress Reactivity, and Brain Activity in Depression Biological Psychiatry. 85: S267. DOI: 10.1016/J.Biopsych.2019.03.677  0.757
2019 Goldstein A, Tozzi L, Sudheimer K, Schatzberg A, Williams L. T13. Functional Impacts of Acute Stress on Negative Affective Circuit Function in Anxiety and Depression Biological Psychiatry. 85: S134. DOI: 10.1016/J.Biopsych.2019.03.336  0.722
2019 Williams N, Heifets B, Bentzley B, Blasey C, Sudheimer K, Lyons D, Schatzberg A. O19. Attenuation of Anti-Suicidal Effects of Ketamine by Opioid Receptor Antagonism Biological Psychiatry. 85: S113. DOI: 10.1016/J.Biopsych.2019.03.284  0.712
2018 Williams NR, Heifets BD, Blasey C, Sudheimer K, Pannu J, Pankow H, Hawkins J, Birnbaum J, Lyons DM, Rodriguez CI, Schatzberg AF. Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism. The American Journal of Psychiatry. appiajp201818020138. PMID 30153752 DOI: 10.1176/Appi.Ajp.2018.18020138  0.712
2018 Roat-Shumway S, Wroolie TE, Watson K, Schatzberg AF, Rasgon NL. Cognitive effects of mifepristone in overweight, euthymic adults with depressive disorders. Journal of Affective Disorders. 239: 242-246. PMID 30025313 DOI: 10.1016/j.jad.2018.07.014  0.301
2018 Block TS, Kushner H, Kalin N, Nelson C, Belanoff J, Schatzberg A. Combined Analysis of Mifepristone for Psychotic Depression: Plasma Levels Associated With Clinical Response. Biological Psychiatry. PMID 29523415 DOI: 10.1016/J.Biopsych.2018.01.008  0.478
2018 Williams NR, Sudheimer KD, Bentzley BS, Pannu J, Stimpson KH, Duvio D, Cherian K, Hawkins J, Scherrer KH, Vyssoki B, DeSouza D, Raj KS, Keller J, Schatzberg AF. High-dose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression. Brain : a Journal of Neurology. PMID 29415152 DOI: 10.1093/Brain/Awx379  0.771
2018 Davis EG, Keller J, Hallmayer J, Pankow HR, Murphy GM, Gotlib IH, Schatzberg AF. Corticotropin-releasing factor 1 receptor haplotype and cognitive features of major depression. Translational Psychiatry. 8: 5. PMID 29317606 DOI: 10.1038/S41398-017-0051-0  0.33
2018 Williams N, Sudheimer K, Bentzley B, Pannu J, Stimpson K, Duvio D, Cherian K, Hawkins J, Scherrer K, Vyssoki B, DeSouza D, Raj K, Keller J, Schatzberg A. T162. High-Dose Spaced Theta-Burst Transcranial Magnetic Stimulation as a Rapid-Acting Anti- Depressant in Highly Refractory Depression Biological Psychiatry. 83: S191. DOI: 10.1016/J.Biopsych.2018.02.499  0.781
2017 Block T, Petrides G, Kushner H, Kalin N, Belanoff J, Schatzberg A. Mifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic Depression. Journal of Clinical Psychopharmacology. PMID 28708736 DOI: 10.1097/Jcp.0000000000000744  0.479
2017 Drysdale AT, Grosenick L, Downar J, Dunlop K, Mansouri F, Meng Y, Fetcho RN, Zebley B, Oathes DJ, Etkin A, Schatzberg AF, Sudheimer K, Keller J, Mayberg HS, Gunning FM, et al. Erratum: Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nature Medicine. 23: 264. PMID 28170383 DOI: 10.1038/nm0217-264d  0.798
2017 Davis E, Keller J, Hallmayer J, Ryan H, Murphy G, Gotlib I, Schatzberg A. 558. Association of CRHR1 TAT Haplotype with Cognitive Features of Major Depressive Disorder Biological Psychiatry. 81: S225-S226. DOI: 10.1016/J.Biopsych.2017.02.1166  0.425
2016 Mamdani F, Rollins B, Morgan L, Myers RM, Barchas JD, Schatzberg AF, Watson SJ, Akil H, Potkin SG, Bunney WE, Vawter MP, Sequeira PA. Variable telomere length across post-mortem human brain regions and specific reduction in the hippocampus of major depressive disorder. Translational Psychiatry. 6: e969. PMID 27922633 DOI: 10.1038/tp.2015.164  0.31
2016 Drysdale AT, Grosenick L, Downar J, Dunlop K, Mansouri F, Meng Y, Fetcho RN, Zebley B, Oathes DJ, Etkin A, Schatzberg AF, Sudheimer K, Keller J, Mayberg HS, Gunning FM, et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nature Medicine. PMID 27918562 DOI: 10.1038/Nm.4246  0.803
2016 Goldstein-Piekarski AN, Korgaonkar MS, Green E, Suppes T, Schatzberg AF, Hastie T, Nemeroff CB, Williams LM. Human amygdala engagement moderated by early life stress exposure is a biobehavioral target for predicting recovery on antidepressants. Proceedings of the National Academy of Sciences of the United States of America. 113: 11955-11960. PMID 27791054 DOI: 10.1073/Pnas.1606671113  0.327
2016 Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, Mohr DC, Schatzberg AF. Major depressive disorder. Nature Reviews. Disease Primers. 2: 16065. PMID 27629598 DOI: 10.1038/nrdp.2016.65  0.587
2016 Keller J, Gomez R, Williams G, Lembke A, Lazzeroni L, Murphy GM, Schatzberg AF. HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cognition. Molecular Psychiatry. PMID 27528460 DOI: 10.1038/mp.2016.120  0.301
2016 Young CB, Chen T, Nusslock R, Keller J, Schatzberg AF, Menon V. Anhedonia and general distress show dissociable ventromedial prefrontal cortex connectivity in major depressive disorder. Translational Psychiatry. 6: e810. PMID 27187232 DOI: 10.1038/Tp.2016.80  0.308
2016 Williams LM, Debattista C, Duchemin AM, Schatzberg AF, Nemeroff CB. Childhood trauma predicts antidepressant response in adults with major depression: data from the randomized international study to predict optimized treatment for depression. Translational Psychiatry. 6: e799. PMID 27138798 DOI: 10.1038/Tp.2016.61  0.357
2016 Williams LM, Goldstein-Piekarski AN, Chowdhry N, Grisanzio KA, Haug NA, Samara Z, Etkin A, O'Hara R, Schatzberg AF, Suppes T, Yesavage J. Developing a clinical translational neuroscience taxonomy for anxiety and mood disorder: protocol for the baseline-follow up Research domain criteria Anxiety and Depression ("RAD") project. Bmc Psychiatry. 16: 68. PMID 26980207 DOI: 10.1186/S12888-016-0771-3  0.564
2016 Schatzberg A. CRH-R1 allelic variation and depressive and psychotic symptoms in major depression Psychoneuroendocrinology. 71: 8-9. DOI: 10.1016/J.Psyneuen.2016.07.031  0.477
2016 Schatzberg A. Lifetime achievement award lecture: The HPA axis in psychotic depression Psychoneuroendocrinology. 71: 5. DOI: 10.1016/J.Psyneuen.2016.07.023  0.507
2015 Williams NR, Schatzberg AF. NMDA antagonist treatment of depression. Current Opinion in Neurobiology. 36: 112-117. PMID 26687375 DOI: 10.1016/J.Conb.2015.11.001  0.59
2015 Mamdani F, Rollins B, Morgan L, Myers RM, Barchas JD, Schatzberg AF, Watson SJ, Akil H, Potkin SG, Bunney WE, Vawter MP, Sequeira PA. Variable telomere length across post-mortem human brain regions and specific reduction in the hippocampus of major depressive disorder. Translational Psychiatry. 5: e636. PMID 26371764 DOI: 10.1038/Tp.2015.134  0.301
2015 Schatzberg A. The chicken and egg of anxiety and depression. Epidemiology and Psychiatric Sciences. 24: 227-9. PMID 25997897 DOI: 10.1017/S2045796015000219  0.378
2015 Schatzberg AF, DeBattista C, Lazzeroni LC, Etkin A, Murphy GM, Williams LM. ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial. The American Journal of Psychiatry. appiajp201514050680. PMID 25815420 DOI: 10.1176/Appi.Ajp.2015.14050680  0.509
2015 Arnow BA, Blasey C, Williams LM, Palmer DM, Rekshan W, Schatzberg AF, Etkin A, Kulkarni J, Luther JF, Rush AJ. Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial. The American Journal of Psychiatry. appiajp201514020181. PMID 25815419 DOI: 10.1176/Appi.Ajp.2015.14020181  0.63
2015 Day CV, Gatt JM, Etkin A, DeBattista C, Schatzberg AF, Williams LM. Cognitive and emotional biomarkers of melancholic depression: An iSPOT-D report. Journal of Affective Disorders. 176: 141-50. PMID 25710095 DOI: 10.1016/J.Jad.2015.01.061  0.557
2015 Saveanu R, Etkin A, Duchemin AM, Goldstein-Piekarski A, Gyurak A, Debattista C, Schatzberg AF, Sood S, Day CV, Palmer DM, Rekshan WR, Gordon E, Rush AJ, Williams LM. The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. Journal of Psychiatric Research. 61: 1-12. PMID 25586212 DOI: 10.1016/J.Jpsychires.2014.12.018  0.777
2015 Day CV, John Rush A, Harris AW, Boyce PM, Rekshan W, Etkin A, DeBattista C, Schatzberg AF, Arnow BA, Williams LM. Impairment and distress patterns distinguishing the melancholic depression subtype: an iSPOT-D report. Journal of Affective Disorders. 174: 493-502. PMID 25554994 DOI: 10.1016/J.Jad.2014.10.046  0.596
2015 Etkin A, Patenaude B, Song YJ, Usherwood T, Rekshan W, Schatzberg AF, Rush AJ, Williams LM. A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 1332-42. PMID 25547711 DOI: 10.1038/Npp.2014.333  0.577
2015 Oathes DJ, Patenaude B, Schatzberg AF, Etkin A. Neurobiological signatures of anxiety and depression in resting-state functional magnetic resonance imaging. Biological Psychiatry. 77: 385-93. PMID 25444162 DOI: 10.1016/J.Biopsych.2014.08.006  0.761
2015 Bunney BG, Li JZ, Walsh DM, Stein R, Vawter MP, Cartagena P, Barchas JD, Schatzberg AF, Myers RM, Watson SJ, Akil H, Bunney WE. Circadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder. Molecular Psychiatry. 20: 48-55. PMID 25349171 DOI: 10.1038/Mp.2014.138  0.345
2015 Sudheimer K, Keller J, Gomez R, Tennakoon L, Reiss A, Garrett A, Kenna H, O'Hara R, Schatzberg AF. Decreased hypothalamic functional connectivity with subgenual cortex in psychotic major depression. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 849-60. PMID 25292261 DOI: 10.1038/Npp.2014.259  0.745
2015 Schatzberg AF. Anna-Monika Award Lecture, DGPPN Kongress, 2013: the role of the hypothalamic-pituitary-adrenal (HPA) axis in the pathogenesis of psychotic major depression. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 16: 2-11. PMID 24933348 DOI: 10.3109/15622975.2014.916414  0.377
2015 Thompson DG, Kesler SR, Sudheimer K, Mehta KM, Thompson LW, Marquett RM, Holland JM, Reiser R, Rasgon N, Schatzberg A, O'Hara RM. FMRI activation during executive function predicts response to cognitive behavioral therapy in older, depressed adults. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 23: 13-22. PMID 24656506 DOI: 10.1016/J.Jagp.2014.02.001  0.725
2015 Parry N, Schatzberg AF. Emerging Approaches in the Treatment of Depression Md Conference Express. 15: 15-16. DOI: 10.1177/1559897715593513  0.372
2015 Staffaroni A, Gomez R, Trettin L, Schatzberg A, Katznelson L, Keller J. A-16The Cognitive Profiles of Cushing's Disease and Psychotic Major Depression Archives of Clinical Neuropsychology. 30: 491.3-492. DOI: 10.1093/arclin/acv047.16  0.315
2014 Schatzberg AF, Blier P, Culpepper L, Jain R, Papakostas GI, Thase ME. An overview of vortioxetine. The Journal of Clinical Psychiatry. 75: 1411-8. PMID 25551236 DOI: 10.4088/Jcp.14027Ah1  0.308
2014 Yuen KW, Garner JP, Carson DS, Keller J, Lembke A, Hyde SA, Kenna HA, Tennakoon L, Schatzberg AF, Parker KJ. Plasma oxytocin concentrations are lower in depressed vs. healthy control women and are independent of cortisol. Journal of Psychiatric Research. 51: 30-6. PMID 24405552 DOI: 10.1016/J.Jpsychires.2013.12.012  0.353
2014 Schatzberg AF, Keller J, Tennakoon L, Lembke A, Williams G, Kraemer FB, Sarginson JE, Lazzeroni LC, Murphy GM. HPA axis genetic variation, cortisol and psychosis in major depression. Molecular Psychiatry. 19: 220-7. PMID 24166410 DOI: 10.1038/mp.2013.129  0.401
2014 Holland JM, Rozalski V, Thompson KL, Tiongson RJ, Schatzberg AF, O'Hara R, Gallagher-Thompson D. The unique impact of late-life bereavement and prolonged grief on diurnal cortisol. The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences. 69: 4-11. PMID 23740094 DOI: 10.1093/geronb/gbt051  0.384
2014 Schatzberg AF, Keller J, Tennakoon L, Lembke A, Williams G, Kraemer FB, Sarginson JE, Lazzeroni LC, Murphy GM. Erratum: HPA axis genetic variation, cortisol and psychosis in major depression Molecular Psychiatry. 19: 1151-1151. DOI: 10.1038/MP.2014.57  0.34
2013 Holland JM, Schatzberg AF, O'Hara R, Marquett RM, Gallagher-Thompson D. Pretreatment cortisol levels predict posttreatment outcomes among older adults with depression in cognitive behavioral therapy. Psychiatry Research. 210: 444-50. PMID 23953171 DOI: 10.1016/J.Psychres.2013.07.033  0.358
2013 Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM, Perlis RH, Mowry BJ, Thapar A, Goddard ME, Witte JS, Absher D, Agartz I, Akil H, Amin F, ... ... Schatzberg AF, et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nature Genetics. 45: 984-94. PMID 23933821 DOI: 10.1038/Ng.2711  0.412
2013 Grieve SM, Korgaonkar MS, Etkin A, Harris A, Koslow SH, Wisniewski S, Schatzberg AF, Nemeroff CB, Gordon E, Williams LM. Brain imaging predictors and the international study to predict optimized treatment for depression: study protocol for a randomized controlled trial. Trials. 14: 224. PMID 23866851 DOI: 10.1186/1745-6215-14-224  0.581
2013 Medina A, Burke S, Thompson RC, Bunney W, Myers RM, Schatzberg A, Akil H, Watson SJ. Glutamate transporters: a key piece in the glutamate puzzle of major depressive disorder. Journal of Psychiatric Research. 47: 1150-6. PMID 23706640 DOI: 10.1016/J.Jpsychires.2013.04.007  0.393
2013 Cohen JD, Nichols T, Keller J, Gomez RG, Schatzberg AF, Reiss AL. Insular cortex abnormalities in psychotic major depression: relationship to gender and psychotic symptoms. Neuroscience Research. 75: 331-9. PMID 23471015 DOI: 10.1016/j.neures.2013.02.005  0.328
2013 Medina A, Seasholtz AF, Sharma V, Burke S, Bunney W, Myers RM, Schatzberg A, Akil H, Watson SJ. Glucocorticoid and mineralocorticoid receptor expression in the human hippocampus in major depressive disorder. Journal of Psychiatric Research. 47: 307-14. PMID 23219281 DOI: 10.1016/J.Jpsychires.2012.11.002  0.389
2013 Kelley R, Garrett A, Cohen J, Gomez R, Lembke A, Keller J, Reiss AL, Schatzberg A. Altered brain function underlying verbal memory encoding and retrieval in psychotic major depression. Psychiatry Research. 211: 119-26. PMID 23149036 DOI: 10.1016/J.Pscychresns.2012.06.008  0.325
2013 Lembke A, Gomez R, Tenakoon L, Keller J, Cohen G, Williams GH, Kraemer FB, Schatzberg AF. The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression. Psychoneuroendocrinology. 38: 115-21. PMID 22727477 DOI: 10.1016/j.psyneuen.2012.05.006  0.375
2012 Rush A, Williams L, Koslow S, Wisniewski S, Cooper N, Nemeroff C, Schatzberg A, Gordon E. O-48 - The international study to predict optimized treatment - in depression: rational, design and initial findings European Psychiatry. 27: 1. DOI: 10.1016/S0924-9338(12)74148-2  0.341
2011 Etkin A, Schatzberg AF. Common abnormalities and disorder-specific compensation during implicit regulation of emotional processing in generalized anxiety and major depressive disorders. The American Journal of Psychiatry. 168: 968-78. PMID 21632648 DOI: 10.1176/Appi.Ajp.2011.10091290  0.585
2011 Williams LM, Rush AJ, Koslow SH, Wisniewski SR, Cooper NJ, Nemeroff CB, Schatzberg AF, Gordon E. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. Trials. 12: 4. PMID 21208417 DOI: 10.7490/F1000Research.1557.1  0.391
2011 Garrett A, Kelly R, Gomez R, Keller J, Schatzberg AF, Reiss AL. Aberrant brain activation during a working memory task in psychotic major depression. The American Journal of Psychiatry. 168: 173-82. PMID 21078708 DOI: 10.1176/Appi.Ajp.2010.09121718  0.385
2010 Janicak PG, Nahas Z, Lisanby SH, Solvason HB, Sampson SM, McDonald WM, Marangell LB, Rosenquist P, McCall WV, Kimball J, O'Reardon JP, Loo C, Husain MH, Krystal A, Gilmer W, ... ... Schatzberg AF, et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimulation. 3: 187-99. PMID 20965447 DOI: 10.1016/J.Brs.2010.07.003  0.314
2010 Lindley S, Cacciapaglia H, Noronha D, Carlson E, Schatzberg A. Monitoring mental health treatment acceptance and initial treatment adherence in veterans: veterans of Operations Enduring Freedom and Iraqi Freedom versus other veterans of other eras. Annals of the New York Academy of Sciences. 1208: 104-13. PMID 20955332 DOI: 10.1111/J.1749-6632.2010.05692.X  0.309
2010 Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology. 30: 135-44. PMID 20520286 DOI: 10.1097/Jcp.0B013E3181D420A7  0.395
2010 Parker KJ, Kenna HA, Zeitzer JM, Keller J, Blasey CM, Amico JA, Schatzberg AF. Preliminary evidence that plasma oxytocin levels are elevated in major depression. Psychiatry Research. 178: 359-62. PMID 20494448 DOI: 10.1016/J.Psychres.2009.09.017  0.388
2010 Rasgon NL, Kenna HA, Williams KE, Powers B, Wroolie T, Schatzberg AF. Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study. Thescientificworldjournal. 10: 321-8. PMID 20191245 DOI: 10.1100/tsw.2010.32  0.375
2010 Etkin A, Prater KE, Hoeft F, Menon V, Schatzberg AF. Failure of anterior cingulate activation and connectivity with the amygdala during implicit regulation of emotional processing in generalized anxiety disorder. The American Journal of Psychiatry. 167: 545-54. PMID 20123913 DOI: 10.1176/Appi.Ajp.2009.09070931  0.46
2010 Reimherr F, Amsterdam J, Dunner D, Adler L, Zhang S, Williams D, Marchant B, Michelson D, Nierenberg A, Schatzberg A, Feldman P. Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetine. Psychiatry Research. 175: 67-73. PMID 19969374 DOI: 10.1016/J.Psychres.2009.01.005  0.439
2010 Sarginson JE, Lazzeroni LC, Ryan HS, Schatzberg AF, Murphy GM. FKBP5 polymorphisms and antidepressant response in geriatric depression. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 153: 554-60. PMID 19676097 DOI: 10.1002/ajmg.b.31019  0.303
2009 Etkin A, Prater KE, Schatzberg AF, Menon V, Greicius MD. Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder. Archives of General Psychiatry. 66: 1361-72. PMID 19996041 DOI: 10.1001/Archgenpsychiatry.2009.104  0.519
2009 Rollins B, Martin MV, Sequeira PA, Moon EA, Morgan LZ, Watson SJ, Schatzberg A, Akil H, Myers RM, Jones EG, Wallace DC, Bunney WE, Vawter MP. Mitochondrial variants in schizophrenia, bipolar disorder, and major depressive disorder. Plos One. 4: e4913. PMID 19290059 DOI: 10.1371/Journal.Pone.0004913  0.342
2009 Etkin A, Keller K, Menon V, Schatzberg A. Failure of Limbic Regulation by the Medial Prefrontal Cortex in Generalized Anxiety Neuroimage. 47: S49. DOI: 10.1016/S1053-8119(09)70101-6  0.485
2008 Schatzberg AF. Achieving remission and favorable outcomes in patients with depression/anxiety and substance use disorders. Cns Spectrums. 13: 10-2. PMID 19317018  0.33
2008 Trivedi MH, Kocsis JH, Thase ME, Morris DW, Wisniewski SR, Leon AC, Gelenberg AJ, Klein DN, Niederehe G, Schatzberg AF, Ninan PT, Keller MB. REVAMP - Research Evaluating the Value of Augmenting Medication with Psychotherapy: rationale and design. Psychopharmacology Bulletin. 41: 5-33. PMID 19015627  0.349
2008 Keller J, Shen L, Gomez RG, Garrett A, Solvason HB, Reiss A, Schatzberg AF. Hippocampal and amygdalar volumes in psychotic and nonpsychotic unipolar depression. The American Journal of Psychiatry. 165: 872-80. PMID 18450931 DOI: 10.1176/Appi.Ajp.2008.07081257  0.409
2008 Krystal JH, Carter CS, Geschwind D, Manji HK, March JS, Nestler EJ, Zubieta JK, Charney DS, Goldman D, Gur RE, Lieberman JA, Roy-Byrne P, Rubinow DR, Anderson SA, Barondes S, ... ... Schatzberg AF, et al. It is time to take a stand for medical research and against terrorism targeting medical scientists. Biological Psychiatry. 63: 725-7. PMID 18371494 DOI: 10.1016/J.Biopsych.2008.03.005  0.486
2008 Kalali A, Vaccarino A, Evans K, Kennedy S, Kobak K, Sills T, Sheehan D, Williams J, Greist J, Schatzberg A. P.2.a.010 The depression inventory development workgroup: results from the second validation study European Neuropsychopharmacology. 18: S298. DOI: 10.1016/S0924-977X(08)70399-7  0.462
2008 Solvason HB, Schatzberg A. Current Prognosis of Depression Biology of Depression: From Novel Insights to Therapeutic Strategies. 223-251. DOI: 10.1002/9783527619672.ch8  0.379
2008 Duman R, Polan HJ, Schatzberg A, Kandel ER. Neurobiologic Foundations of Mood Disorders Psychiatry: Third Edition. 1: 339-353. DOI: 10.1002/9780470515167.ch21  0.369
2007 Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, Lam RW, Lépine JP, Möller HJ, Nutt DJ, Rouillon F, Schatzberg AF, Thase ME. Which antidepressants have demonstrated superior efficacy? A review of the evidence. International Clinical Psychopharmacology. 22: 323-9. PMID 17917550 DOI: 10.1097/Yic.0B013E3282Eff7E0  0.353
2007 Kocsis JH, Thase ME, Trivedi MH, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Dunner DL, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, et al. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. The Journal of Clinical Psychiatry. 68: 1014-23. PMID 17685736 DOI: 10.4088/Jcp.V68N0706  0.304
2007 Schatzberg AF. Safety and tolerability of antidepressants: weighing the impact on treatment decisions. The Journal of Clinical Psychiatry. 68: 26-34. PMID 17640155  0.351
2007 Keller J, Schatzberg AF, Maj M. Current issues in the classification of psychotic major depression. Schizophrenia Bulletin. 33: 877-85. PMID 17548842 DOI: 10.1093/schbul/sbm065  0.416
2007 Michelson D, Adler LA, Amsterdam JD, Dunner DL, Nierenberg AA, Reimherr FW, Schatzberg AF, Kelsey DK, Williams DW. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry. 68: 582-7. PMID 17474814  0.359
2007 Greicius MD, Flores BH, Menon V, Glover GH, Solvason HB, Kenna H, Reiss AL, Schatzberg AF. Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus. Biological Psychiatry. 62: 429-37. PMID 17210143 DOI: 10.1016/J.Biopsych.2006.09.020  0.349
2007 Cunningham M, Schatzberg AF. Agomelatine Demonstrates Broad Efficacy in Depression Md Conference Express. 7: 15-16. DOI: 10.1177/155989770700700208  0.401
2007 Green AI, Schatzberg AF. Joseph J Schildkraut, 1934–2006 Neuropsychopharmacology. 32: 1855-1856. DOI: 10.1038/Sj.Npp.1301474  0.392
2006 Schatzberg AF. New paradigm for treating recurrent depression: from symptom control to managing enduring vulnerabilities. Cns Spectrums. 11: 22-7. PMID 17146415  0.371
2006 Rush AJ, Kraemer HC, Sackeim HA, Fava M, Trivedi MH, Frank E, Ninan PT, Thase ME, Gelenberg AJ, Kupfer DJ, Regier DA, Rosenbaum JF, Ray O, Schatzberg AF. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 31: 1841-53. PMID 16794566 DOI: 10.1038/Sj.Npp.1301131  0.312
2006 Schatzberg A, Roose S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 14: 361-70. PMID 16582045 DOI: 10.1097/01.Jgp.0000194645.70869.3B  0.44
2006 Keller J, Flores B, Gomez RG, Solvason HB, Kenna H, Williams GH, Schatzberg AF. Cortisol circadian rhythm alterations in psychotic major depression. Biological Psychiatry. 60: 275-81. PMID 16458262 DOI: 10.1016/j.biopsych.2005.10.014  0.411
2006 Keller J, Gomez RG, Kenna HA, Poesner J, DeBattista C, Flores B, Schatzberg AF. Detecting psychotic major depression using psychiatric rating scales. Journal of Psychiatric Research. 40: 22-9. PMID 16165160 DOI: 10.1016/j.jpsychires.2005.07.003  0.364
2006 Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 31: 628-36. PMID 16160710 DOI: 10.1038/Sj.Npp.1300884  0.344
2006 Ohayon MM, Schatzberg AF. Fine-tuning our diagnosis and treatment of depression Journal of Psychiatric Research. 40: 281-282. DOI: 10.1016/j.jpsychires.2006.04.005  0.378
2005 Debattista C, Solomon A, Arnow B, Kendrick E, Tilston J, Schatzberg AF. The efficacy of divalproex sodium in the treatment of agitation associated with major depression. Journal of Clinical Psychopharmacology. 25: 476-9. PMID 16160625 DOI: 10.1097/01.jcp.0000177552.21338.b0  0.434
2005 Roose SP, Schatzberg AF. The efficacy of antidepressants in the treatment of late-life depression. Journal of Clinical Psychopharmacology. 25: S1-7. PMID 16027554 DOI: 10.1097/01.jcp.0000162807.84570.6b  0.302
2005 Schatzberg AF, Rush AJ, Arnow BA, Banks PL, Blalock JA, Borian FE, Howland R, Klein DN, Kocsis JH, Kornstein SG, Manber R, Markowitz JC, Miller I, Ninan PT, Rothbaum BO, et al. Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. Archives of General Psychiatry. 62: 513-20. PMID 15867104 DOI: 10.1001/Archpsyc.62.5.513  0.403
2004 Schatzberg AF. Employing pharmacologic treatment of bipolar disorder to greatest effect. The Journal of Clinical Psychiatry. 65: 15-20. PMID 15554791  0.384
2004 Murphy GM, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Archives of General Psychiatry. 61: 1163-9. PMID 15520364 DOI: 10.1001/archpsyc.61.11.1163  0.334
2004 Killen JD, Robinson TN, Ammerman S, Hayward C, Rogers J, Samuels D, Schatzberg AF. Major depression among adolescent smokers undergoing treatment for nicotine dependence. Addictive Behaviors. 29: 1517-26. PMID 15451121 DOI: 10.1016/j.addbeh.2004.02.029  0.31
2004 Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, Van Campen LE, Sanger TM, Tollefson GD. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology. 24: 365-73. PMID 15232326 DOI: 10.1097/01.jcp.0000130557.08996.7a  0.319
2004 Young EA, Altemus M, Lopez JF, Kocsis JH, Schatzberg AF, DeBattista C, Zubieta JK. HPA axis activation in major depression and response to fluoxetine: a pilot study. Psychoneuroendocrinology. 29: 1198-204. PMID 15219644 DOI: 10.1016/j.psyneuen.2004.02.002  0.365
2004 Posener JA, Charles DeBattista, Veldhuis JD, Province MA, Williams GH, Schatzberg AF. Process irregularity of cortisol and adrenocorticotropin secretion in men with major depressive disorder. Psychoneuroendocrinology. 29: 1129-37. PMID 15219636 DOI: 10.1016/J.Psyneuen.2004.01.004  0.35
2004 Schatzberg AF. Pharmacologic treatments of major depression: are two mechanisms really better than one? The Journal of Clinical Psychiatry. 65: 3-4. PMID 15046535  0.406
2004 Fleming SK, Blasey C, Schatzberg AF. Neuropsychological correlates of psychotic features in major depressive disorders: a review and meta-analysis. Journal of Psychiatric Research. 38: 27-35. PMID 14690768 DOI: 10.1016/S0022-3956(03)00100-6  0.313
2003 Schatzberg AF. Introduction: treating depression and anxiety to remission. The Journal of Clinical Psychiatry. 64: 3-4. PMID 14658983  0.4
2003 Nemeroff CB, Heim CM, Thase ME, Klein DN, Rush AJ, Schatzberg AF, Ninan PT, McCullough JP, Weiss PM, Dunner DL, Rothbaum BO, Kornstein S, Keitner G, Keller MB. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proceedings of the National Academy of Sciences of the United States of America. 100: 14293-6. PMID 14615578 DOI: 10.1073/Pnas.2336126100  0.407
2003 Schatzberg AF. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. The Journal of Clinical Psychiatry. 64: 30-7. PMID 14552654  0.379
2003 Murphy GM, Kremer C, Rodrigues H, Schatzberg AF. The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively intact elderly depressed patients. Biological Psychiatry. 54: 665-73. PMID 14512205 DOI: 10.1016/S0006-3223(03)00174-4  0.36
2003 Mallick R, Chen J, Entsuah AR, Schatzberg AF. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. The Journal of Clinical Psychiatry. 64: 321-30. PMID 12716275  0.367
2003 Killen JD, Fortmann SP, Schatzberg A, Hayward C, Varady A. Onset of major depression during treatment for nicotine dependence. Addictive Behaviors. 28: 461-70. PMID 12628619 DOI: 10.1016/S0306-4603(01)00266-0  0.468
2003 Schatzberg AF. New approaches to managing psychotic depression. The Journal of Clinical Psychiatry. 64: 19-23. PMID 12625801  0.429
2003 Parker KJ, Schatzberg AF, Lyons DM. Neuroendocrine aspects of hypercortisolism in major depression. Hormones and Behavior. 43: 60-6. PMID 12614635 DOI: 10.1016/S0018-506X(02)00016-8  0.386
2003 DeBattista C, Solvason HB, Poirier J, Kendrick E, Schatzberg AF. A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. Journal of Clinical Psychopharmacology. 23: 27-30. PMID 12544372 DOI: 10.1097/00004714-200302000-00005  0.351
2003 Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Archives of General Psychiatry. 60: 39-47. PMID 12511171  0.362
2003 Schatzberg AF. Introduction: Recent Developments in Achieving Depression Remission Journal of Clinical Psychiatry. 64: 4.  0.399
2002 McDonald WM, Salzman C, Schatzberg AF. Depression in the elderly. Psychopharmacology Bulletin. 36: 112-22. PMID 12490827  0.391
2002 Ohayon MM, Schatzberg AF. Prevalence of depressive episodes with psychotic features in the general population. The American Journal of Psychiatry. 159: 1855-61. PMID 12411219 DOI: 10.1176/appi.ajp.159.11.1855  0.389
2002 Kocsis JH, Schatzberg A, Rush AJ, Klein DN, Howland R, Gniwesch L, Davis SM, Harrison W. Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo. Archives of General Psychiatry. 59: 723-8. PMID 12150648 DOI: 10.1001/Archpsyc.59.8.723  0.425
2002 Thase ME, Rush AJ, Manber R, Kornstein SG, Klein DN, Markowitz JC, Ninan PT, Friedman ES, Dunner DL, Schatzberg AF, Borian FE, Trivedi MH, Keller MB. Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression. The Journal of Clinical Psychiatry. 63: 493-500. PMID 12088160 DOI: 10.4088/Jcp.V63N0605  0.36
2002 Davidson JRT, Gadde KM, Fairbank JA, Ranga Rama Krishnan K, Califf RM, Binanay C, Parker CB, Pugh N, Hartwell TD, Vitiello B, Ritz L, Severe J, Cole JO, De Battista C, Murali Doraiswamy P, ... ... Schatzberg AF, et al. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: A randomized controlled trial Journal of the American Medical Association. 287: 1807-1814. PMID 11939866 DOI: 10.1001/JAMA.287.14.1807  0.325
2002 Schatzberg AF, Prather MR, Keller MB, Rush AJ, Laird LK, Wright CW. Clinical use of nefazodone in major depression: a 6-year perspective. The Journal of Clinical Psychiatry. 63: 18-31. PMID 11890561  0.357
2002 Charney DS, Nemeroff CB, Lewis L, Laden SK, Gorman JM, Laska EM, Borenstein M, Bowden CL, Caplan A, Emslie GJ, Evans DL, Geller B, Grabowski LE, Herson J, Kalin NH, ... ... Schatzberg AF, et al. National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. Archives of General Psychiatry. 59: 262-70. PMID 11879164 DOI: 10.1001/Archpsyc.59.3.262  0.314
2002 Thase ME, Rush AJ, Howland RH, Kornstein SG, Kocsis JH, Gelenberg AJ, Schatzberg AF, Koran LM, Keller MB, Russell JM, Hirschfeld RM, LaVange LM, Klein DN, Fawcett J, Harrison W. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Archives of General Psychiatry. 59: 233-9. PMID 11879161 DOI: 10.1001/Archpsyc.59.3.233  0.325
2002 Hirschfeld RM, Dunner DL, Keitner G, Klein DN, Koran LM, Kornstein SG, Markowitz JC, Miller I, Nemeroff CB, Ninan PT, Rush AJ, Schatzberg AF, Thase ME, Trivedi MH, Borian FE, et al. Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biological Psychiatry. 51: 123-33. PMID 11822991 DOI: 10.1016/S0006-3223(01)01291-4  0.395
2002 Schatzberg AF. Major Depression: Causes or Effects? American Journal of Psychiatry. 159: 1077-1079. DOI: 10.1176/APPI.AJP.159.7.1077  0.407
2002 Schatzberg AF, Kremer C, Rodrigues HE, Murphy GM, Bari M, Vista C, Baumel B, Blake L, Cheren S, DeBattista C, Eisner L, Falk W, Hand S, Hassman H, Kirby L, et al. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients American Journal of Geriatric Psychiatry. 10: 541-550. DOI: 10.1097/00019442-200209000-00007  0.375
2002 Fava M, Falk W, Schatzberg A, Kremer C, Murphy G, Rodrigues H. Mirtazapine versus paroxetine in elderly patients with anxious depression European Neuropsychopharmacology. 12: 425-426. DOI: 10.1016/S0924-977X(02)80739-8  0.484
2002 Mallick R, Schatzberg A. Depression-free days as a flexible measure of response, remission, and elimination of residual symptoms: A pooled analysis of venlafaxine, SSRIs, and placebo European Neuropsychopharmacology. 12: 235. DOI: 10.1016/S0924-977X(02)80285-1  0.329
2002 Schwartz G, Such P, Schatzberg A. Reboxetine vs venlafaxine in the treatment of severe major depression European Neuropsychopharmacology. 12: 204-205. DOI: 10.1016/S0924-977X(02)80208-5  0.403
2002 DeBattista C, Rothschild AJ, Schatzberg AF. A dynamic algorithm for the treatment of psychotic major depression Psychiatric Annals. 32: 681-691.  0.313
2001 Posener JA, DeBattista C, Williams GH, Schatzberg AF. Cortisol feedback during the HPA quiescent period in patients with major depression. The American Journal of Psychiatry. 158: 2083-5. PMID 11729034  0.341
2001 Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. Rapid reversal of psychotic depression using mifepristone. Journal of Clinical Psychopharmacology. 21: 516-21. PMID 11593077  0.409
2001 Belanoff JK, Kalehzan M, Sund B, Fleming Ficek SK, Schatzberg AF. Cortisol activity and cognitive changes in psychotic major depression. The American Journal of Psychiatry. 158: 1612-6. PMID 11578992  0.406
2001 Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). The Journal of Clinical Endocrinology and Metabolism. 86: 3568-73. PMID 11502780 DOI: 10.1210/Jcem.86.8.7740  0.34
2001 Koran LM, Gelenberg AJ, Kornstein SG, Howland RH, Friedman RA, DeBattista C, Klein D, Kocsis JH, Schatzberg AF, Thase ME, Rush AJ, Hirschfeld RM, LaVange LM, Keller MB. Sertraline versus imipramine to prevent relapse in chronic depression. Journal of Affective Disorders. 65: 27-36. PMID 11426506 DOI: 10.1016/S0165-0327(00)00272-X  0.353
2001 Schatzberg A, Debattista C, Murphy G, Kremer C, Rodrigues H. Mirtazapine versus paroxetine in elderly depressed patients European Neuropsychopharmacology. 11: S195. DOI: 10.1016/S0924-977X(01)80152-8  0.382
2001 Schatzberg A, Belanoff J, Murphy G. Recent research on pharmacogenetics in geriatric depression and mifepristone in delusional depression European Neuropsychopharmacology. 11: S108-S109. DOI: 10.1016/S0924-977X(01)80022-5  0.4
2000 Montgomery SA, Schatzberg AF, Guelfi JD, Kasper S, Nemeroff C, Swann A, Zajecka J. Pharmacotherapy of depression and mixed states in bipolar disorder. Journal of Affective Disorders. 59: S39-S56. PMID 11121826 DOI: 10.1016/S0165-0327(00)00178-6  0.411
2000 Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, Gelenberg AJ, Davis SM, Harrison WM, Keller MB. Gender differences in treatment response to sertraline versus imipramine in chronic depression. The American Journal of Psychiatry. 157: 1445-52. PMID 10964861  0.374
2000 Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, Gelenberg AJ, Ryan CE, Hess AL, Harrison W, Davis SM, Keller MB. Gender differences in chronic major and double depression. Journal of Affective Disorders. 60: 1-11. PMID 10940442 DOI: 10.1016/S0165-0327(99)00158-5  0.388
2000 Posener JA, DeBattista C, Williams GH, Chmura Kraemer H, Kalehzan BM, Schatzberg AF. 24-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. Archives of General Psychiatry. 57: 755-60. PMID 10920463  0.324
2000 DeBattista C, Posener JA, Kalehzan BM, Schatzberg AF. Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study. The American Journal of Psychiatry. 157: 1334-7. PMID 10910802  0.376
2000 Schatzberg AF. Clinical efficacy of reboxetine in major depression. The Journal of Clinical Psychiatry. 61: 31-8. PMID 10910015  0.38
2000 Schatzberg AF, Posener JA, DeBattista C, Kalehzan BM, Rothschild AJ, Shear PK. Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness. The American Journal of Psychiatry. 157: 1095-100. PMID 10873917 DOI: 10.1176/appi.ajp.157.7.1095  0.398
2000 Green AI, Tohen M, Patel JK, Banov M, DuRand C, Berman I, Chang H, Zarate C, Posener J, Lee H, Dawson R, Richards C, Cole JO, Schatzberg AF. Clozapine in the treatment of refractory psychotic mania. The American Journal of Psychiatry. 157: 982-6. PMID 10831480 DOI: 10.1176/Appi.Ajp.157.6.982  0.495
2000 Hirschfeld RM, Montgomery SA, Keller MB, Kasper S, Schatzberg AF, Möller HJ, Healy D, Baldwin D, Humble M, Versiani M, Montenegro R, Bourgeois M. Social functioning in depression: a review. The Journal of Clinical Psychiatry. 61: 268-75. PMID 10830147 DOI: 10.4088/Jcp.V61N0405  0.321
2000 DeBattista C, Solvason HB, Breen JA, Schatzberg AF. Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression. Journal of Clinical Psychopharmacology. 20: 274-5. PMID 10770475 DOI: 10.1097/00004714-200004000-00029  0.398
2000 Schatzberg A, DeBattista C, Posener J. Glucocorticoids & cognition in depression European Neuropsychopharmacology. 10: 180. DOI: 10.1016/S0924-977X(00)80088-7  0.335
2000 Schatzberg AF, DeBattista C, Kalchzan M, Posener J. HPA axis activity and cognition in major depression Psychoneuroendocrinology. 25: S18. DOI: 10.1016/S0306-4530(00)90094-5  0.338
1999 Klein DN, Schatzberg AF, McCullough JP, Dowling F, Goodman D, Howland RH, Markowitz JC, Smith C, Thase ME, Rush AJ, LaVange L, Harrison WM, Keller MB. Age of onset in chronic major depression: relation to demographic and clinical variables, family history, and treatment response. Journal of Affective Disorders. 55: 149-57. PMID 10628884 DOI: 10.1016/S0165-0327(99)00020-8  0.356
1999 Schatzberg AF, DeBattista C. Phenomenology and treatment of agitation. The Journal of Clinical Psychiatry. 60: 17-20. PMID 10418809  0.402
1999 Klein DN, Schatzberg AF, McCullough JP, Keller MB, Dowling F, Goodman D, Howland RH, Markowitz JC, Smith C, Miceli R, Harrison WM. Early- versus late-onset dythymic disorder: comparison in out-patients with superimposed major depressive episodes. Journal of Affective Disorders. 52: 187-96. PMID 10357032 DOI: 10.1016/S0165-0327(98)00079-2  0.309
1999 Schatzberg AF. Antidepressant effectiveness in severe depression and melancholia. The Journal of Clinical Psychiatry. 60: 14-21; discussion 22. PMID 10086479  0.416
1998 Miller IW, Keitner GI, Schatzberg AF, Klein DN, Thase ME, Rush AJ, Markowitz JC, Schlager DS, Kornstein SG, Davis SM, Harrison WM, Keller MB. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. The Journal of Clinical Psychiatry. 59: 608-19. PMID 9862607 DOI: 10.4088/Jcp.V59N1108  0.393
1998 Rush AJ, Koran LM, Keller MB, Markowitz JC, Harrison WM, Miceli RJ, Fawcett JA, Gelenberg AJ, Hirschfeld RM, Klein DN, Kocsis JH, McCullough JP, Schatzberg AF, Thase ME. The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. The Journal of Clinical Psychiatry. 59: 589-97. PMID 9862605  0.316
1998 Keller MB, Kocsis JH, Thase ME, Gelenberg AJ, Rush AJ, Koran L, Schatzberg A, Russell J, Hirschfeld R, Klein D, McCullough JP, Fawcett JA, Kornstein S, LaVange L, Harrison W. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. Jama. 280: 1665-72. PMID 9831997 DOI: 10.1001/Jama.280.19.1665  0.439
1998 Schatzberg AF, Samson JA, Rothschild AJ, Bond TC, Regier DA. McLean Hospital depression research facility: early-onset phobic disorders and adult-onset major depression. The British Journal of Psychiatry. Supplement. 29-34. PMID 9829014  0.409
1998 Montgomery SA, Schatzberg AF. Introduction. Reboxetine: a new selective antidepressant for the treatment of depression. The Journal of Clinical Psychiatry. 59: 3. PMID 9818622  0.383
1998 Rush AJ, Koran LM, Keller MB, Markowitz JC, Harrison WM, Miceli RJ, Fawcett JA, Gelenberg AJ, Hirschfeld RMA, Klein DN, Kocsis JH, McCullough JP, Schatzberg AF, Thase ME. The Treatment of Chronic Depression, Part 1 The Journal of Clinical Psychiatry. 59: 589-597. DOI: 10.4088/Jcp.V59N1106  0.331
1997 Debattista C, Solvason HB, Belanoff J, Schatzberg AF. Treatment of psychotic depression. The American Journal of Psychiatry. 154: 1625-6. PMID 9356580  0.413
1997 Kocsis J, Schatzberg A, Rush A, Korstein S, Klein D, Hirschfeld R. Maintenance therapy of chronic depression: A placebo-controlled trial of sertraline Biological Psychiatry. 42: 240S. DOI: 10.1016/S0006-3223(97)87896-1  0.313
1997 Thase M, Keller M, Gelenberg A, Hirschfeld R, Schatzberg A. Double-blind crossover antidepressant study: Sertraline vs. imipramine Biological Psychiatry. 42: 230S. DOI: 10.1016/S0006-3223(97)87842-0  0.369
1996 Schatzberg AF. Treatment of severe depression with the selective serotonin reuptake inhibitors. Depression and Anxiety. 4: 182-9. PMID 9166650 DOI: 10.1002/(SICI)1520-6394(1996)4:4<182::AID-DA4>3.0.CO;2-H  0.342
1995 Kornstein SG, Schatzberg AF, Yonkers KA, Thase ME, Keitner GI, Ryan CE, Schlager D. Gender differences in presentation of chronic major depression. Psychopharmacology Bulletin. 31: 711-8. PMID 8851644  0.351
1995 Salzman C, Wolfson AN, Schatzberg A, Looper J, Henke R, Albanese M, Schwartz J, Miyawaki E. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. Journal of Clinical Psychopharmacology. 15: 23-9. PMID 7714224 DOI: 10.1097/00004714-199502000-00005  0.401
1995 Keller MB, Harrison W, Fawcett JA, Gelenberg A, Hirschfeld RM, Klein D, Kocsis JH, McCullough JP, Rush AJ, Schatzberg A. Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of undertreatment in the community. Psychopharmacology Bulletin. 31: 205-12. PMID 7491369  0.407
1995 Schatzberg AF, Posener JA, Rothschild AJ. The Role of Dopamine in Psychotic Depression Clinical Neuropharmacology. 18: S66-S73. DOI: 10.1097/00002826-199501001-00009  0.325
1994 Hirschfeld RM, Schatzberg AF. Long-term management of depression. The American Journal of Medicine. 97: 33S-38S. PMID 7992825  0.369
1994 Debattista C, Schatzberg AF. An Algorithm for the Treatment of Major Depression and its Subtypes Psychiatric Annals. 24: 341-347. DOI: 10.3928/0048-5713-19940701-08  0.336
1993 Green AI, Alam MY, Sobieraj JT, Pappalardo KM, Waternaux C, Salzman C, Schatzberg AF, Schildkraut JJ. Clozapine response and plasma catecholamines and their metabolites. Psychiatry Research. 46: 139-49. PMID 8483973 DOI: 10.1016/0165-1781(93)90016-A  0.451
1993 Bowden CL, Schatzberg AF, Rosenbaum A, Contreras SA, Samson JA, Dessain E, Sayler M. Fluoxetine and desipramine in major depressive disorder. Journal of Clinical Psychopharmacology. 13: 305-11. PMID 8227488  0.379
1993 Rothschild AJ, Samson JA, Bond TC, Luciana MM, Schildkraut JJ, Schatzberg AF. Hypothalamic-pituitary-adrenal axis activity and 1-year outcome in depression. Biological Psychiatry. 34: 392-400. PMID 8218607 DOI: 10.1016/0006-3223(93)90184-F  0.352
1992 Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? The American Journal of Psychiatry. 149: 733-45. PMID 1590491  0.435
1992 Rothschild AJ, Schatzberg AF. Theoretical basis for response to steroid suppression in major depression. Journal of Clinical Psychopharmacology. 12: 142-4. PMID 1573041  0.397
1992 Schildkraut JJ, Schatzberg AF, Samson JA, Rosenbaum A, Bowden CL. Norepinephrine output and metabolism in depressed patients during antidepressant treatments. Clinical Neuropharmacology. 15: 323A-324A. PMID 1498855  0.362
1992 Schatzberg AF. Recent developments in the acute somatic treatment of major depression. The Journal of Clinical Psychiatry. 53: 20-5. PMID 1347770  0.382
1992 Schatzberg AF, Bowden CL, Rosenbaum AH, Samson JA, Dessain E, Schildkraut JJ. EFFECTS OF FLUOXETINE AND DESIPRAMINE ON URINARY CATECHOLAMINE AND METABOLITE EXCRETION IN MAJOR DEPRESSION Clinical Neuropharmacology. 15: 415B. DOI: 10.1097/00002826-199202001-00807  0.388
1992 bowden c, schatzberg a, rosenbaum a, contreras s, schildkraut j, dessain e. Effects Of Fluoxetine & Desipramine On Platelet Imipramine Binding In Major Depression Clinical Neuropharmacology. 15. DOI: 10.1097/00002826-199202001-00637  0.427
1991 Mooney JJ, Schatzberg AF, Cole JO, Samson JA, Waternaux C, Gerson B, Pappalardo KM, Schildkraut JJ. Urinary 3-methoxy-4-hydroxyphenylglycol and the depression-type score as predictors of differential responses to antidepressants. Journal of Clinical Psychopharmacology. 11: 339-43. PMID 1770151  0.327
1990 Schatzberg AF, Samson JA, Rothschild AJ, Luciana MM, Bruno RF, Bond TC. Depression secondary to anxiety: findings from the McLean Hospital Depression Research Facility. The Psychiatric Clinics of North America. 13: 633-49. PMID 2281010 DOI: 10.1016/S0193-953X(18)30340-X  0.406
1989 Rothschild AJ, Benes F, Hebben N, Woods B, Luciana M, Bakanas E, Samson JA, Schatzberg AF. Relationships between brain CT scan findings and cortisol in psychotic and nonpsychotic depressed patients. Biological Psychiatry. 26: 565-75. PMID 2790096 DOI: 10.1016/0006-3223(89)90081-4  0.343
1989 Schatzberg AF, Samson JA, Bloomingdale KL, Orsulak PJ, Gerson B, Kizuka PP, Cole JO, Schildkraut JJ. Toward a biochemical classification of depressive disorders. X. Urinary catecholamines, their metabolites, and D-type scores in subgroups of depressive disorders. Archives of General Psychiatry. 46: 260-8. PMID 2783211 DOI: 10.1001/Archpsyc.1989.01810030066009  0.34
1988 Schatzberg AF, Rothschild AJ. The roles of glucocorticoid and dopaminergic systems in delusional (psychotic) depression. Annals of the New York Academy of Sciences. 537: 462-71. PMID 3059936  0.354
1987 Schatzberg AF, Rothschild AJ, Langlais PJ, Lerbinger JE, Schildkraut JJ, Cole JO. Psychotic and nonpsychotic depressions: II. Platelet MAO activity, plasma catecholamines, cortisol, and specific symptoms. Psychiatry Research. 20: 155-64. PMID 3575560 DOI: 10.1016/0165-1781(87)90007-2  0.308
1987 Schatzberg AF, Dessain E, O'Neil P, Katz DL, Cole JO. Recent studies on selective serotonergic antidepressants: trazodone, fluoxetine, and fluvoxamine. Journal of Clinical Psychopharmacology. 7: 44S-49S. PMID 3123528 DOI: 10.1097/00004714-198712001-00005  0.376
1987 Rothschild AJ, Schatzberg AF, Langlais PJ, Lerbinger JE, Miller MM, Cole JO. Psychotic and nonpsychotic depressions: I. Comparison of plasma catecholamines and cortisol measures. Psychiatry Research. 20: 143-53. PMID 2883694  0.352
1986 Bond TC, Rothschild AJ, Lerbinger J, Schatzberg AF. Delusional depression, family history, and DST response: a pilot study. Biological Psychiatry. 21: 1239-46. PMID 3756274 DOI: 10.1016/0006-3223(86)90306-9  0.356
1985 Samson JA, Gudeman JE, Schatzberg AF, Kizuka PP, Orsulak PJ, Cole JO, Schildkraut JJ. Toward a biochemical classification of depressive disorders--VIII. Platelet monoamine oxidase activity in subtypes of depressions. Journal of Psychiatric Research. 19: 547-55. PMID 4078757 DOI: 10.1016/0022-3956(85)90072-X  0.39
1985 Schatzberg AF, Rothschild AJ, Langlais PJ, Bird ED, Cole JO. A corticosteroid/dopamine hypothesis for psychotic depression and related states. Journal of Psychiatric Research. 19: 57-64. PMID 2859366  0.316
1985 Mooney JJ, Cole JO, Schatzberg AF, Gerson B, Schildkraut JJ. Pretreatment urinary MHPG levels as predictors of antidepressant responses to alprazolam. The American Journal of Psychiatry. 142: 366-7. PMID 2857533  0.388
1984 Schatzberg AF, Rothschild AJ, Bond TC, Cole JO. The DST in psychotic depression: diagnostic and pathophysiologic implications. Psychopharmacology Bulletin. 20: 362-4. PMID 6473631  0.413
1983 Schatzberg AF, Rothschild AJ, Stahl JB, Bond TC, Rosenbaum AH, Lofgren SB, MacLaughlin RA, Sullivan MA, Cole JO. The dexamethasone suppression test: identification of subtypes of depression. The American Journal of Psychiatry. 140: 88-91. PMID 6847992  0.404
1983 Rosenbaum AH, Maruta T, Schatzberg AF, Orsulak PJ, Jiang NS, Cole JO, Schildkraut JJ. Toward a biochemical classification of depressive disorders, VII: urinary free cortisol and urinary MHPG in depressions. The American Journal of Psychiatry. 140: 314-8. PMID 6829802  0.342
1983 Schatzberg AF, Cole JO. Benzodiazepines in the treatment of depressive, borderline personality, and schizophrenic disorders. British Journal of Clinical Pharmacology. 17S-22S. PMID 6133529 DOI: 10.1111/J.1365-2125.1981.Tb01834.X  0.488
1982 Rothschild AJ, Schatzberg AF, Rosenbaum AH, Stahl JB, Cole JO. The dexamethasone suppression test as a discriminator among subtypes of psychotic patients. The British Journal of Psychiatry : the Journal of Mental Science. 141: 471-4. PMID 7150883  0.307
1982 Gudeman JE, Schatzberg AF, Samson JA, Orsulak PJ, Cole JO, Schildkraut JJ. Toward a biochemical classification of depressive disorders, VI: Platelet MAO activity and clinical symptoms in depressed patients. The American Journal of Psychiatry. 139: 630-3. PMID 7072851  0.349
1982 Schatzberg AF, Orsulak PJ, Rosenbaum AH, Maruta T, Kruger ER, Cole JO, Schildkraut JJ. Toward a biochemical classification of depressive disorders, V: Heterogeneity of unipolar depressions. The American Journal of Psychiatry. 139: 471-5. PMID 7065292  0.404
1981 COLE JO, SCHATZBERG AF, SNIFFIN C, ZOLNER J, COLE JP. Trazodone in Treatment-Resistant Depression: An Open Study Journal of Clinical Psychopharmacology. 1: 49S-54S. DOI: 10.1097/00004714-198111001-00010  0.361
1981 Schatzberg AF, Rosenbaum AH, Orsulak PJ, Rohde WA, Maruta T, Kruger ER, Cole JO, Schildkraut JJ. Toward a biochemical classification of depressive disorders - III: Pretreatment urinary MHPG levels as predictors of response to treatment with maprotiline Psychopharmacology. 75: 34-38. DOI: 10.1007/BF00433498  0.358
1978 Schildkraut JJ, Orsulak PJ, LaBrie RA, Schatzberg AF, Gudeman JE, Cole JO, Rohde WA. Toward a biochemical classification of depressive disorders. II. Application of multivariate discriminant function analysis to data on urinary catecholamines and metabolites. Archives of General Psychiatry. 35: 1436-9. PMID 727879 DOI: 10.1001/Archpsyc.1978.01770360040004  0.398
1978 Schildkraut JJ, Orsulak PJ, Schatzberg AF, Gudeman JE, Cole JO, Rohde WA, LaBrie RA. Toward a biochemical classification of depressive disorders. I. Differences in urinary excretion of MHPG and other catecholamine metabolites in clinically defined subtypes of depressions. Archives of General Psychiatry. 35: 1427-33. PMID 727878 DOI: 10.1001/Archpsyc.1978.01770360031003  0.424
1978 Schatzberg AF, Cole JO. Benzodiazepines in depressive disorders. Archives of General Psychiatry. 35: 1359-65. PMID 30428 DOI: 10.1001/ARCHPSYC.1978.01770350085008  0.444
Show low-probability matches.